This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tricoli, J. V. Articles by Conley, B. A. Search for Related Content PubMed PubMed Citation Articles by Tricoli, J. V. Articles by Conley, B. A. Related Collections Clinical Research Clinical Research: Imaging, Diagnosis, and Prognosis

Detection of Prostate Cancer and Predicting Progression

Current and Future Diagnostic Markers

¹ Diagnostics Research Branch, Cancer Diagnosis Program, National Cancer Institute, Rockville, Maryland; ² Aerodigestive Clinical Cancer Research Section, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland; and ³ The EMMES Corporation, Rockville, Maryland

Carcinoma of the prostate is the second leading cause of male cancer-related death in the United States. Better indicators of prostate cancer presence and progression are needed to avoid unnecessary treatment, predict disease course, and develop more effective therapy. Numerous molecular markers have been described in human serum, urine, seminal fluid, and histological specimens that exhibit varying capacities to detect prostate cancer and predict disease course. However, to date, few of these markers have been adequately validated for clinical use. The purpose of this review is to examine the current status of these markers in prostate cancer and to assess the diagnostic potential for future markers from identified genes and molecules that display loss, mutation, or alteration in expression between tumor and normal prostate tissues. In this review we cite 91 molecular markers that display some level of correlation with prostate cancer presence, disease progression, cancer recurrence, prediction of response to therapy, and/or disease-free survival. We suggest criteria to consider when selecting a marker for further development as a clinical tool and discuss five examples of markers (chromogranin A, glutathione S-transferase 1, prostate stem cell antigen, prostate-specific membrane antigen, and telomerase reverse transcriptase) that fulfill some of these criteria. Finally, we discuss how to conduct evaluations of candidate prostate cancer markers and some of the issues involved in the validation process.

This article has been cited by other articles:

				B. Lin, A. G. Utleg, K. Gravdal, J. T. White, O. J. Halvorsen, W. Lu, L. D. True, R. Vessella, P. H. Lange, P. S. Nelson, et al. WDR19 Expression is Increased in Prostate Cancer Compared with Normal Cells, but Low-Intensity Expression in Cancers is Associated with Shorter Time to Biochemical Failures and Local Recurrence Clin. Cancer Res., March 1, 2008; 14(5): 1397 - 1406. [Abstract] [Full Text] [PDF]

				R. W. Veltri, M. C. Miller, S. Isharwal, C. Marlow, D. V. Makarov, and A. W. Partin Prediction of Prostate-Specific Antigen Recurrence in Men with Long-term Follow-up Postprostatectomy Using Quantitative Nuclear Morphometry Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 102 - 110. [Abstract] [Full Text] [PDF]

				A. P. Kumar, S. Bhaskaran, M. Ganapathy, K. Crosby, M. D. Davis, P. Kochunov, J. Schoolfield, I-T. Yeh, D. A. Troyer, and R. Ghosh Akt/cAMP-Responsive Element Binding Protein/Cyclin D1 Network: A Novel Target for Prostate Cancer Inhibition in Transgenic Adenocarcinoma of Mouse Prostate Model Mediated by Nexrutine, a Phellodendron Amurense Bark Extract Clin. Cancer Res., May 1, 2007; 13(9): 2784 - 2794. [Abstract] [Full Text] [PDF]

				H. Wang, M. Li, W. Lin, W. Wang, Z. Zhang, E. R. Rayburn, J. Lu, D. Chen, X. Yue, F. Shen, et al. Extracellular Activity of Cyclic AMP-Dependent Protein Kinase as a Biomarker for Human Cancer Detection: Distribution Characteristics in a Normal Population and Cancer Patients Cancer Epidemiol. Biomarkers Prev., April 1, 2007; 16(4): 789 - 795. [Abstract] [Full Text] [PDF]

				V. U. Bai, A. Kaseb, S. Tejwani, G. W. Divine, E. R. Barrack, M. Menon, A. B. Pardee, and G. P.-V. Reddy Identification of prostate cancer mRNA markers by averaged differential expression and their detection in biopsies, blood, and urine PNAS, February 13, 2007; 104(7): 2343 - 2348. [Abstract] [Full Text] [PDF]

				J. C. Bemis, N. F. Alejandro, D. A. Nazarenko, A. I. Brooks, R. B. Baggs, and T. A. Gasiewicz TCDD-Induced Alterations in Gene Expression Profiles of the Developing Mouse Paw Do Not Influence Morphological Differentiation of This Potential Target Tissue Toxicol. Sci., January 1, 2007; 95(1): 240 - 248. [Abstract] [Full Text] [PDF]

				J. R. Reeves, H. Dulude, C. Panchal, L. Daigneault, and D. M. Ramnani Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy. Clin. Cancer Res., October 15, 2006; 12(20): 6018 - 6022. [Abstract] [Full Text] [PDF]

				G. E. Garcia, H.-G. Wisniewski, M. S. Lucia, N. Arevalo, T. J. Slaga, S. L. Kraft, R. Strange, and A. P. Kumar 2-Methoxyestradiol Inhibits Prostate Tumor Development in Transgenic Adenocarcinoma of Mouse Prostate: Role of Tumor Necrosis Factor-{alpha}-Stimulated Gene 6 Clin. Cancer Res., February 1, 2006; 12(3): 980 - 988. [Abstract] [Full Text] [PDF]

				A. Ryo, H. Uemura, H. Ishiguro, T. Saitoh, A. Yamaguchi, K. Perrem, Y. Kubota, K. P. Lu, and I. Aoki Stable Suppression of Tumorigenicity by Pin1-Targeted RNA Interference in Prostate Cancer Clin. Cancer Res., October 15, 2005; 11(20): 7523 - 7531. [Abstract] [Full Text] [PDF]

				P. J. Bastian, J. Ellinger, A. Wellmann, N. Wernert, L. C. Heukamp, S. C. Muller, and A. von Ruecker Diagnostic and Prognostic Information in Prostate Cancer with the Help of a Small Set of Hypermethylated Gene Loci Clin. Cancer Res., June 1, 2005; 11(11): 4097 - 4106. [Abstract] [Full Text] [PDF]

				V. Fradet, L. Lessard, L. R. Begin, P. Karakiewicz, A.-M. M. Masson, and F. Saad Nuclear Factor-{kappa}B Nuclear Localization Is Predictive of Biochemical Recurrence in Patients with Positive Margin Prostate Cancer Clin. Cancer Res., December 15, 2004; 10(24): 8460 - 8464. [Abstract] [Full Text] [PDF]